Close menu

August 17th, 2022 | 13:05 CEST

Over 200% share price potential? Analysts on BioNTech, BASF and Saturn Oil + Gas

  • Mining
  • Oil
  • Biotechnology
Photo credits:

The stock markets are friendly this week and the summer rally continues. Analysts still see room for improvement in the BioNTech share. The German biotech leader could be in for a golden autumn. Its product pipeline is promising. High energy prices and a looming gas shock in winter are causing trouble for the share of BASF. Analysts are also divided: "outperform" or "sell"? At Saturn Oil & Gas, free cash flow could almost reach the level of current market capitalization in the coming year. Therefore, analysts predict a revaluation potential and a share price potential of more than 200%. After all, investor legend Warren Buffett also backs oil producers.

time to read: 3 minutes | Author: Fabian Lorenz
ISIN: BIONTECH SE SPON. ADRS 1 | US09075V1026 , BASF SE NA O.N. | DE000BASF111 , Saturn Oil + Gas Inc. | CA80412L8832

Table of contents:

    Saturn Oil & Gas: Analysts see over 200% share price potential

    After a virtual roadshow, analysts at Eight Capital are confident in the potential of Saturn Oil & Gas shares. With a target price of CAD 7.50, they recommend buying the shares of the Canadian oil producer. Currently, the share is quoted at CAD 2.37. Saturn Oil & Gas is on track to create additional value from the acquired assets. Therefore, the current valuation is a buying opportunity. The market is still paying too little attention to free cash flow growth and the possibility of debt reduction. Moreover, there would be other internal catalysts to justify a re-rating of the stock.

    Ongoing extended reach horizontal drilling at the Viking project would significantly increase profitability. This could also be applied to the Alberta project. These are examples of the Company being a world-class operator. Saturn Oil & Gas is on track to meet its second-half 2022 production guidance of 12.3 MBOE/d. With that, analysts also expect the free cash flow to turn around. They added that the valuation and FCF return profile of Saturn Oil & Gas continues to be at a WTI price of USD 65. Free cash flow is expected to increase to CAD 131 million as early as next year. Currently, the entire company is valued at CAD 140 million. Interesting: Investor legend Waren Buffett also seems convinced by the oil sector. The Oracle from Omaha has consistently increased his stake in the US oil company Occidental in recent months.

    BioNTech stock USD 312 or just USD 200?

    The BioNTech share is currently digesting the slightly disappointing quarterly figures. The analysts at Berenberg expect that the share price could soon head north again. They have renewed the buy recommendation and set a price target of USD 312. The sales target with the COVID-19 vaccine is still achievable, even if the revenues in the second quarter were below expectations. The booster vaccines adapted to new variants are expected to be approved by the authorities in the US and Europe in September. The order books should then also fill up again quickly. Goldman Sachs analysts are more cautious about BioNTech's potential. They rate the stock as "Neutral" with a price target of USD 200. After second-quarter revenue and earnings figures came in below expectations, earnings forecasts for 2022 to 2025 were reduced. Currently, the BioNTech share is trading at around EUR 160.

    BASF: Can raw material and energy prices be passed on?

    Low levels, high energy prices, a gas levy and an impending gas shortage in winter: Hardly any German company is suffering as much as BASF from the current situation. And with the Company, so are its shareholders. The share is trading at EUR 44, not far from its 5-year low. And yet, against the immense risks, it is surprising that the analysts at Bernstein still see a price potential of over 50%. Their optimism is based on BASF's US agricultural business. The latest US Department of Agriculture data on corn and soybean inventories suggest that the German group's business is picking up. Therefore, the analysts have set a price target of EUR 72. UBS, on the other hand, advises selling BASF shares. Their price target is EUR 37. Although the chemical group is better prepared for the low water levels of the Rhine than in 2018, production restrictions can no longer be ruled out. In particular, the supply of coal is a cause for concern.

    BioNTech is currently recovering from relatively weak quarterly figures and could generate new share price gains in the fall with its new booster vaccines. Should Saturn Oil & Gas achieve a free cash flow of CAD 131 million in the coming year - as expected by Eight Capital - the stock would be a real bargain. At present, only investors with strong nerves are likely to buy BASF.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author

    Related comments:

    Commented by Juliane Zielonka on April 12th, 2024 | 07:00 CEST

    AI in healthcare with Evotec, Defence Therapeutics, Bayer: Revolutionary advances and medical breakthroughs

    • Biotechnology
    • Pharma
    • AI

    Artificial intelligence (AI) is gaining momentum in the healthcare sector. AI-based systems can use medical databases to save valuable time in research, enabling companies like Defence Therapeutics to go to market faster than others. In oncology research, the Canadian company has just achieved a breakthrough that gives hope to many cancer patients. AI-assisted diagnoses allow diseases to be detected earlier and treated more effectively, leading to improved quality of life for patients. Precision medicine in strong partnership networks is Evotec's focus. The share is particularly popular with hedge fund managers. Analyzing medical images and data in real-time and detecting even the smallest deviations or anomalies is the top priority for Bayer AG in collaboration with Google Cloud. Which companies are convincing investors the most?


    Commented by Fabian Lorenz on April 11th, 2024 | 07:30 CEST

    Panic at AIXTRON and NEL! Is Kraken Energy an AI beneficiary?

    • Mining
    • Uranium
    • nuclear
    • renewableenergies
    • AI

    AIXTRON shares lost more than 5% yesterday. In addition to the price slide on the NASDAQ, a negative analyst comment added to the negative sentiment. Both the rating and target price of the AIXTRON share were significantly reduced. The same applies to Nel. The hydrogen specialist's recovery attempt was mercilessly stifled, and the share lost over 15%. The lack of incoming orders, in particular, is making analysts nervous. In contrast, Kraken Energy could soon be seen as an AI beneficiary. After all, Elon Musk is not the only one warning of an energy crisis and calling for the expansion of nuclear energy. Voices are getting louder that the computing power required for artificial intelligence will cause energy consumption to explode. In order to prevent a blackout, many countries are turning to nuclear power.


    Commented by Fabian Lorenz on April 11th, 2024 | 07:00 CEST

    Out of defense, into gold!? Renk, Barrick Gold, Desert Gold

    • Mining
    • Gold
    • defense
    • armaments

    On Tuesday, German defense stocks were shaken briefly and sharply. In a flash crash, Renk, Rheinmetall and Hensoldt fell by more than 10%. This indicates that defense stocks have run hot. The future prospects for the companies are undeniably positive, but a consolidation is in order. Gold is an entirely different story. The price of the precious metal is at record levels, but the shares of gold producers are still a long way from their 2020 highs. This applies to the heavyweights like Barrick Gold and Endeavour Mining, but even more so to the explorers. One of the promising explorers is Desert Gold. The Company operates in an attractive region, is on the verge of becoming a Tier 1 mine producer, and is a takeover candidate. Barrick Gold is one of many companies that could make a move on Desert Gold.